Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912722470> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2912722470 endingPage "S489" @default.
- W2912722470 startingPage "S488" @default.
- W2912722470 abstract "Purpose: To estimate differences in health care costs between Crohn's disease (CD) patients (pts) and controls and to examine differences in CD costs by prescription therapy. Methods: Administrative claims data from geographically diverse private US health plans with service dates between Jan 1, 2002 and Dec 31, 2005 were utilized. CD pts (ICD-9-CM code 555.x) were identified and matched to controls in a 1:5 ratio on age, gender, health plan, and duration of enrollment. Members with at least 1-year of continuous enrollment after a CD diagnosis were included; total costs (2005 US$) were calculated by summing the amount paid by the health plan for medical services and pharmaceuticals. CD pts were grouped by drug regimen as follows: steroids, immunosuppressants (IMMS), infliximab, any combination of the 3 drug classes, and no CD-treatment or treatment not including studied regimens. Average medical and pharmaceutical cost per pt per day was estimated in each group and projected annually. Results: 9,302 CD pts and 46,510 matched controls were identified. Total annual cost per pt was nearly 4 times higher in the CD group ($11,454) than the control group ($3,028, P < 0.01). Costs for medical services accounted for greater than 80% of total costs in each group, $9,762 and $2,494, respectively. CD pts not receiving any of the studied therapies had considerably lower costs for medical services and pharmaceuticals compared to the study groups (Table). Costs of medical services among CD pts receiving a steroid in combination with another therapy were substantially higher compared to both monotherapy and combination therapies excluding steroids.Table: Mean Per Patient Per Day and Annual Costs by Drug RegimenConclusion: CD pts incur significantly greater costs than a similar general population. CD pts on no treatment or not receiving studied regimens incur fewer costs suggesting that they may be experiencing remission or mild symptoms. The use of steroids is associated with significantly higher medical costs, which may be suggestive of uncontrolled symptoms or flares requiring medical resources." @default.
- W2912722470 created "2019-02-21" @default.
- W2912722470 creator A5017457971 @default.
- W2912722470 creator A5029640796 @default.
- W2912722470 creator A5040157496 @default.
- W2912722470 creator A5061169811 @default.
- W2912722470 creator A5063806172 @default.
- W2912722470 creator A5087574931 @default.
- W2912722470 date "2007-09-01" @default.
- W2912722470 modified "2023-09-25" @default.
- W2912722470 title "Cost of Treating Crohnʼs Disease" @default.
- W2912722470 doi "https://doi.org/10.14309/00000434-200709002-01009" @default.
- W2912722470 hasPublicationYear "2007" @default.
- W2912722470 type Work @default.
- W2912722470 sameAs 2912722470 @default.
- W2912722470 citedByCount "0" @default.
- W2912722470 crossrefType "journal-article" @default.
- W2912722470 hasAuthorship W2912722470A5017457971 @default.
- W2912722470 hasAuthorship W2912722470A5029640796 @default.
- W2912722470 hasAuthorship W2912722470A5040157496 @default.
- W2912722470 hasAuthorship W2912722470A5061169811 @default.
- W2912722470 hasAuthorship W2912722470A5063806172 @default.
- W2912722470 hasAuthorship W2912722470A5087574931 @default.
- W2912722470 hasConcept C126322002 @default.
- W2912722470 hasConcept C133425853 @default.
- W2912722470 hasConcept C160735492 @default.
- W2912722470 hasConcept C162324750 @default.
- W2912722470 hasConcept C175444787 @default.
- W2912722470 hasConcept C182299520 @default.
- W2912722470 hasConcept C2426938 @default.
- W2912722470 hasConcept C2777138892 @default.
- W2912722470 hasConcept C2779134260 @default.
- W2912722470 hasConcept C2779280984 @default.
- W2912722470 hasConcept C2780958618 @default.
- W2912722470 hasConcept C2781413609 @default.
- W2912722470 hasConcept C2992755240 @default.
- W2912722470 hasConcept C50522688 @default.
- W2912722470 hasConcept C71924100 @default.
- W2912722470 hasConcept C98274493 @default.
- W2912722470 hasConceptScore W2912722470C126322002 @default.
- W2912722470 hasConceptScore W2912722470C133425853 @default.
- W2912722470 hasConceptScore W2912722470C160735492 @default.
- W2912722470 hasConceptScore W2912722470C162324750 @default.
- W2912722470 hasConceptScore W2912722470C175444787 @default.
- W2912722470 hasConceptScore W2912722470C182299520 @default.
- W2912722470 hasConceptScore W2912722470C2426938 @default.
- W2912722470 hasConceptScore W2912722470C2777138892 @default.
- W2912722470 hasConceptScore W2912722470C2779134260 @default.
- W2912722470 hasConceptScore W2912722470C2779280984 @default.
- W2912722470 hasConceptScore W2912722470C2780958618 @default.
- W2912722470 hasConceptScore W2912722470C2781413609 @default.
- W2912722470 hasConceptScore W2912722470C2992755240 @default.
- W2912722470 hasConceptScore W2912722470C50522688 @default.
- W2912722470 hasConceptScore W2912722470C71924100 @default.
- W2912722470 hasConceptScore W2912722470C98274493 @default.
- W2912722470 hasLocation W29127224701 @default.
- W2912722470 hasOpenAccess W2912722470 @default.
- W2912722470 hasPrimaryLocation W29127224701 @default.
- W2912722470 hasRelatedWork W1542252223 @default.
- W2912722470 hasRelatedWork W2006318665 @default.
- W2912722470 hasRelatedWork W2032015456 @default.
- W2912722470 hasRelatedWork W2032850606 @default.
- W2912722470 hasRelatedWork W2039552229 @default.
- W2912722470 hasRelatedWork W2053866477 @default.
- W2912722470 hasRelatedWork W2086957417 @default.
- W2912722470 hasRelatedWork W2106133713 @default.
- W2912722470 hasRelatedWork W2170056941 @default.
- W2912722470 hasRelatedWork W2402613124 @default.
- W2912722470 hasVolume "102" @default.
- W2912722470 isParatext "false" @default.
- W2912722470 isRetracted "false" @default.
- W2912722470 magId "2912722470" @default.
- W2912722470 workType "article" @default.